KMT2A and breast carcinoma: Combined PI3K and MLL inhibition reduced cell viability in multiple PI3K-activated breast cancer models (Fig. 4A and B), which was confirmed with additional PI3K and MLL1 inhibitors (Supplementary Fig. S4A).